First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811.

Chung HC, Bang YJ, S Fuchs C, Qin SK, Satoh T, Shitara K, Tabernero J, Van Cutsem E, Alsina M, Cao ZA, Lu J, Bhagia P, Shih CS, Janjigian YY

Open source

DOI: 10.2217/fon-2020-0737
Published: 2021 Feb
Container: Future oncology (London, England)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.2217/fon-2020-0737,
  title = {First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811.},
  author = {Chung HC and Bang YJ and S Fuchs C and Qin SK and Satoh T and Shitara K and Tabernero J and Van Cutsem E and Alsina M and Cao ZA and Lu J and Bhagia P and Shih CS and Janjigian YY},
  year = {2021},
  journal = {Future oncology (London, England)},
  doi = {10.2217/fon-2020-0737},
  url = {https://doi.org/10.2217/fon-2020-0737}
}

RIS

TY  - JOUR
TI  - First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811.
AU  - Chung HC
AU  - Bang YJ
AU  - S Fuchs C
AU  - Qin SK
AU  - Satoh T
AU  - Shitara K
AU  - Tabernero J
AU  - Van Cutsem E
AU  - Alsina M
AU  - Cao ZA
AU  - Lu J
AU  - Bhagia P
AU  - Shih CS
AU  - Janjigian YY
PY  - 2021
JO  - Future oncology (London, England)
DO  - 10.2217/fon-2020-0737
UR  - https://doi.org/10.2217/fon-2020-0737
ER  -

APA

HC, C., YJ, B., C, S. F., SK, Q., T, S., K, S., J, T., E, V. C., M, A., ZA, C., J, L., P, B., CS, S., & YY, J. (2021). First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811.. Future oncology (London, England). https://doi.org/10.2217/fon-2020-0737

Source records

pubmed · retrieved 2026-09-26T22:37:17.424Z